Stallergenes Greer announced that the company has entered into a research collaboration on the discovery of biomarkers of AIT efficacy with Imperial College London. This long-term research collaboration, which combines the long-standing expertise of Stallergenes Greer in AIT with the prestigious research capabilities of Imperial College London, aims to push the boundaries of allergic patient care by identifying biomarkers of AIT efficacy and expanding the knowledge of the pathophysiology of allergic diseases and their treatment with AIT.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | +0.14% | +29.68% |
2023 | Nestle Reportedly May Sell Peanut Allergy Therapy to Stallergenes | CI |
2023 | Stallergenes Greer Ltd Initiates European Paediatric Phase III Study with Staloral Birch | CI |
1st Jan change | Capi. | |
---|---|---|
+29.68% | 0 | |
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
+18.82% | 2.38B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B |
- Stock Market
- Equities
- STAGR Stock
- News Stallergenes Greer
- Stallergenes Greer Strengthens Precision Medicine Approach in Allergen Immunotherapy with Imperial College London Research Collaboration